Skip to main content
SpringerLink
Log in

Heart Failure and Sudden Death

  • Chapter
  • First Online:
Electrical Diseases of the Heart

  • 2097 Accesses

Abstract

Syndrome of congestive heart failure is a clinical manifestation of many cardiac disease processes when the cardiovascular compensatory mechanisms are no longer able to maintain homeostasis. Approximately five million people in the United States have heart failure and over 550,000 of patients are diagnosed with heart failure for the first time each year. The Framingham heart study reported 62 and 42 % 5-year survival rates, respectively, for men and women with newly diagnosed congestive heart failure in the early 1970s. These mortality rates were six to seven times higher than that of age-matched general population. Of the total mortality, approximately 40–50 % were sudden deaths. The trending in the incidence and survival with heart failure among 11,311 subjects in the Framingham heart study during a 50-year interval has been updated. Heart failure occurred in 1,075 study participants between 1950 and 1999. The 5-year mortality rate among men declined from 70 % in the period from 1950 to 1969 to 59 % in the period from 1990 to 1999, whereas the respective rates among woman declined from 57 to 45 %. Although the relative declining of mortality is encouraging, likely a result of the better understanding of the disease patho-physiology and improvement of the medical and device therapy, the growing epidemics of heart failure has been increasingly recognized in the United States and around the globe.

The topic of heart failure and sudden death is enormously broad. Many specific and related topics are discussed in other chapters of the book. In this chapter, we will provide an overview on the following relevant issues: (1) mode of death in patients with heart failure; (2) arrhythmogenic substrates and triggers of malignant arrhythmias causing sudden death; (3) risk stratification schemes in identifying patients at increased risk of sudden death in heart failure; (4) outcomes from sudden death prevention clinical trials; and (5) a summary of current clinical management in sudden death prevention in heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46(6):e1–82. Erratum in J Am Coll Cardiol. 2006 Apr 7;47(7):1503–1505.

    Google Scholar 

  2. McKee P. The natural history of congestive heart failure: the Framingham study. N Engl J Heart. 1971;285(26):1441–6.

    Article  CAS  Google Scholar 

  3. Kannel W, Plehn J, Cupples L. Cardiac failure and sudden death in the Framingham study. Am Heart J. 1988;115(4):869–75.

    Article  PubMed  CAS  Google Scholar 

  4. Levy D et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402.

    Article  PubMed  Google Scholar 

  5. Luu M et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675–80.

    Article  PubMed  CAS  Google Scholar 

  6. Cha YM, Shen WK. Heart failure and sudden death. In: Gussak I, Antzelevitch C, editors. Electrical Diseases of the Heart. Springer Publishers; 2008. pp. 874.

    Article  Google Scholar 

  7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.

    Article  Google Scholar 

  8. Mitchel L et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol. 2002;39(8):1323–8.

    Article  Google Scholar 

  9. Hunt SA. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46(6):e1-82.

    Google Scholar 

  10. Hunt S et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guide­lines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–235.

    Article  PubMed  Google Scholar 

  11. Cubbon RM et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction/clinical perspective. Circ Heart Fail. 2011;4(4):396–403.

    Article  PubMed  Google Scholar 

  12. Nabauer M, Barth A, Kaab S. A second calcium-independent transient outward current present in human left ventricular myocardium. Circulation. 1998;98(1):231.

    Google Scholar 

  13. Priebe L, Beuckelmann D. Stimulation study of cellular electric properties in heart failure. Circ Res. 1998;82(11):1206–23.

    Article  PubMed  CAS  Google Scholar 

  14. Tsui Y, Opthof T, Kamiya K. Pacing-induced heart failure causes a reduction of delayed rectifier potassium current along with decreases in calcium and transient outward currents in rabbit ventricle. Cardiovasc Res. 2000;48:300–9.

    Article  Google Scholar 

  15. Beuckelmann D. Ca(2+)-currents and intracellular (Ca2+)i-transients in single ventricular myocytes isolated from terminally failing human myocardium. Basic Res Cardiol. 1992;87(1):235–43.

    PubMed  Google Scholar 

  16. Mews T, Ravens U. L-type calcium currents of human myocytes from ventricle of non-failing hearts and from atrium. J Mol Cell Cardiol. 1994;26:1307–20.

    Article  Google Scholar 

  17. Mukherjee R et al. Changes in L-type calcium channel abundance and function during the transition to pacing-induced congestive heart failure. Cardiovasc Res. 1998;37:432–44.

    Article  PubMed  CAS  Google Scholar 

  18. Bers D, Eisner D, Valdivia H. Sarcoplasmic reticulum CA2+ and heart failure: roles of diastolic leak and Ca2+ transport. Circ Res. 2003;93:487–90.

    Article  PubMed  CAS  Google Scholar 

  19. Vermeulen J, McGuire M, Opthof T. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res. 1994;28:1547–54.

    Article  PubMed  CAS  Google Scholar 

  20. Poelzing S, Rosenbaum D. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol. 2004;287:H1762–70.

    CAS  Google Scholar 

  21. Guth L. Regeneration in the mammalian peri­pheral nervous system. Physiol Rev. 1956;36:441–78.

    PubMed  CAS  Google Scholar 

  22. Meiri K. Growth-associated protein, GAP-43, a polypeptide that is induced when neurons extend axons, is a component of growth cones and corresponds to pp 46, a major polypeptide of a subcellular fraction enriched in growth cones. Proc Natl Acad Sci USA. 1986;83(10):3537–41.

    Article  PubMed  CAS  Google Scholar 

  23. Oh Y et al. Spatial distribution of nerve sprouting after myocardial infarction in mice. Heart J. 2006;3(6):728–36.

    Google Scholar 

  24. Zhou S. Mechanisms of cardiac nerve sprouting after myocardial infarction in dogs. Circ Res. 2004;95:76–83.

    Article  PubMed  CAS  Google Scholar 

  25. Chen LS, Zhou S, Fishbein MC, et al. New perspectives on the role of autonomic nervous system in the genesis of arrhythmias. J Cardiovasc Electrophysiol. 2006;17:1–5.

    Article  Google Scholar 

  26. Cao J. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation. 2000;101:1960–9.

    Article  PubMed  CAS  Google Scholar 

  27. Cao J. Nerve sprouting and sudden cardiac death. Circ Res. 2000;86:816–21.

    Article  PubMed  CAS  Google Scholar 

  28. Cha Y. Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure. Heart Rhythm. 2005;2(9):984–90.

    Article  PubMed  Google Scholar 

  29. Jardine D. A neural mechanism for sudden death after myocardial infarction. Clin Auton Res. 2003;13:339–41.

    Article  PubMed  CAS  Google Scholar 

  30. Schwartz P, Priori S. Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Philadelphia: W.B. Saunders Company; 1990. p. 330–43.

    Google Scholar 

  31. de Bakker J et al. Slow conduction in the infarcted human heart ‘Zigzag’ course of activation. Circulation. 1993;88:915–26.

    Article  PubMed  Google Scholar 

  32. Stevenson W et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation. 1993;88:1647–60.

    Article  PubMed  CAS  Google Scholar 

  33. Gardner P. Electrophysiologic and anatomic basis for fractionated electrograms recorded from healed myocardial. Circulation. 1985;72:596–611.

    Article  PubMed  CAS  Google Scholar 

  34. Brembilla-Perrot B, Houriez P, Claudon O. Long-term reproducibility of ventricular tachycardia induction with electrophysiological testing in patients with coronary artery disease and depressed left ventricular ejection fraction. PACE. 2000;23:47–53.

    Article  PubMed  CAS  Google Scholar 

  35. de Bakker JM et al. Fractionated electrograms in dilated cardiomyopathy: origin and relation to abnormal conduction. J Am Coll Cardiol. 1996;27(5):1071–8.

    Article  PubMed  Google Scholar 

  36. Caceres J. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation. 1989;79:256–70.

    Article  PubMed  CAS  Google Scholar 

  37. Cooper H. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311–5.

    Article  PubMed  CAS  Google Scholar 

  38. Gettes L. Electrolyte abnormalities underlying lethal ventricular arrhythmias. Circulation. 1992;85:70–6.

    Google Scholar 

  39. Reiter M et al. Electrophysiological effects of acute dilatation in the isolated rabbit heart: cycle length-dependent effects on ventricular refractoriness and conduction velocity. Circulation. 1997;96:4050–6.

    Article  PubMed  CAS  Google Scholar 

  40. Dean J, Lab M. Arrhythmia in heart failure: role of mechanically induced changes in electrophysiology. Lancet. 1989;1:1309.

    Article  PubMed  CAS  Google Scholar 

  41. Koilpillai C, Quinones MA, Greenberg B, et al. Relation of ventricular size and function to heart failure status and ventricular dysrhythmia in patients with severe left ventricular dysfunction. Am J Cardiol. 1996;77:606–11.

    Article  PubMed  CAS  Google Scholar 

  42. Wu J, Zipes D. Transmural reentry during global acute ischemia and reperfusion in canine ventricular muscle. Am J Physiol. 2001;280:H2717–25.

    CAS  Google Scholar 

  43. Buxton A et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341(25):1882–90.

    Article  PubMed  CAS  Google Scholar 

  44. Moss A et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.

    Article  PubMed  Google Scholar 

  45. Solomon S et al. Effect of Candesartan on cause-specific mortality in heart failure patients. Circulation. 2004;110:2180–3.

    Article  PubMed  CAS  Google Scholar 

  46. Brendorp B et al. QT dispersion has no prognostic information for patients with advanced congestive heart failure and reduced left ventricular systolic function. Circulation. 2001;103:831–5.

    Article  PubMed  CAS  Google Scholar 

  47. Brooksby P et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. Eur Heart J. 1999;20:1335–41.

    Article  PubMed  CAS  Google Scholar 

  48. Kitamura H et al. Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2002;39(2):295–300.

    Article  PubMed  Google Scholar 

  49. Bloomfield D et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy. Circulation. 2004;110:1885–9.

    Article  PubMed  Google Scholar 

  50. Doust J et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J. 2005;330:1–9.

    Article  Google Scholar 

  51. Klingenheben T et al. Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure. Lancet. 2000;356(9230):651–2.

    Article  PubMed  CAS  Google Scholar 

  52. Woo M, Stevenson W, Moser D. Complex heart rate variability and serum norepinephrine levels in patients with advanced heart failure. J Mol Cell Cardiol. 1994;23:565–9.

    Article  CAS  Google Scholar 

  53. La Rovere M et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation. 2003;107:565–70.

    Article  PubMed  Google Scholar 

  54. Yamada T et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41(2):231–8.

    Article  PubMed  Google Scholar 

  55. Berger R, Huelsmann M, Streckes K. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur J Clin Invest. 2005;35(1):24–31.

    Article  PubMed  CAS  Google Scholar 

  56. Waagstein F et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37(10):1022–36.

    Article  PubMed  CAS  Google Scholar 

  57. Hjalmarson A et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA. 2000;283(10):1295–302.

    Article  PubMed  CAS  Google Scholar 

  58. Packer M et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.

    Article  PubMed  CAS  Google Scholar 

  59. Investigators C. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90.

    Article  Google Scholar 

  60. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–67.

    Article  Google Scholar 

  61. Poole-Wilson P et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.

    Article  PubMed  CAS  Google Scholar 

  62. Ellison K et al. Effect of B-blocking therapy on outcome in the multicenter unsustained tachycardia trial (MUSTT). Circulation. 2002;106:2694–9.

    Article  PubMed  CAS  Google Scholar 

  63. Pfeffer M et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–66.

    Article  PubMed  CAS  Google Scholar 

  64. Granger C et al. Effects of candesartan in patients with chronic heart failure and reduced left-­ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772–6.

    Article  PubMed  CAS  Google Scholar 

  65. McMurray J et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–71.

    Article  PubMed  CAS  Google Scholar 

  66. Vusuf S et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362(9386):777–81.

    Article  Google Scholar 

  67. St. John Sutton M et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577–82.

    Article  Google Scholar 

  68. Domanski M, Exner D, Borkowf C. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. J Mol Cell Cardiol. 1999;33:598.

    Article  CAS  Google Scholar 

  69. Doval H et al. Lancet. 1994;344(8921):493–8.

    Article  PubMed  CAS  Google Scholar 

  70. Singh S, Fletcher R, Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333(2):77–82.

    Article  PubMed  CAS  Google Scholar 

  71. Bardy G et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.

    Article  PubMed  CAS  Google Scholar 

  72. Poole-Wilson P et al. Mode of death in heart ­failure: findings from the ATLAS trial. Heart J. 2003;89(1):42–8.

    Article  CAS  Google Scholar 

  73. Massie B et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation. 1996;93(12):2128–34.

    Article  PubMed  CAS  Google Scholar 

  74. Cairns J et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet. 1997;349(9053):675–82.

    Article  PubMed  CAS  Google Scholar 

  75. Julian D et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349(9053):667–74.

    Article  PubMed  CAS  Google Scholar 

  76. Torp-Pedersen C. Classification of sudden and arrhythmia death. Pacing Clin Electrophysiol. 1997;20:2545–52.

    Article  PubMed  CAS  Google Scholar 

  77. Echt D et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. JAMA. 1991;324(12):781–8.

    CAS  Google Scholar 

  78. Teo K, Usuf S, Furberg C. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA. 1993;270:1589–95.

    Article  PubMed  CAS  Google Scholar 

  79. Investigators A. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576–84.

    Article  Google Scholar 

  80. Kuck K et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–54.

    Article  PubMed  CAS  Google Scholar 

  81. Connolly S et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.

    Article  PubMed  CAS  Google Scholar 

  82. Knight B, Goyal R, Pelosi F. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol. 1999;33(7):1964–70.

    Article  PubMed  CAS  Google Scholar 

  83. Moss A. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–40.

    Article  PubMed  CAS  Google Scholar 

  84. Packer DL et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure. Circulation. 2009;120(22):2170–6.

    Article  PubMed  CAS  Google Scholar 

  85. Moss A et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Heart. 1996;335(26):1933–40.

    Article  CAS  Google Scholar 

  86. Bigger J, Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after ­coronary-artery bypass graft surgery. N Engl J Heart. 1997;337(22):1569–75.

    Article  Google Scholar 

  87. Hohnloser S et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481–8.

    Article  PubMed  CAS  Google Scholar 

  88. Kadish A et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.

    Article  PubMed  CAS  Google Scholar 

  89. Bradley D et al. Cardiac resynchronization and death from progressive heart failure: a metaanalysis of randomized controlled trials. JAMA. 2003;289:730–40.

    Article  PubMed  Google Scholar 

  90. Bristow M et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.

    Article  PubMed  CAS  Google Scholar 

  91. Cleland J et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.

    Article  PubMed  CAS  Google Scholar 

  92. Moss AJ et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.

    Article  PubMed  Google Scholar 

  93. Zareba W et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT)/Clinical Perspective. Circulation. 2011;123(10):1061–72.

    Article  PubMed  Google Scholar 

  94. Poole JE et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–17.

    Article  PubMed  CAS  Google Scholar 

  95. Reddy VY et al. Short-term results of substrate mapping and radiofrequency ablation of ischemic ventricular tachycardia using a saline-­irrigated catheter. J Am Coll Cardiol. 2003;41(12):2228–36.

    Article  PubMed  Google Scholar 

  96. Calkins H et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. J Am Coll Cardiol. 2000;35(7):1905–14.

    Article  PubMed  CAS  Google Scholar 

  97. Stevenson WG et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction. Circulation. 2008;118(25):2773–82.

    Article  PubMed  Google Scholar 

  98. Carbucicchio C et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators. Circulation. 2008;117(4):462–9.

    Article  PubMed  Google Scholar 

  99. Kuck K-H et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2013;375(9708):31–40.

    Article  Google Scholar 

  100. Reddy VY et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357(26):2657–65.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55041, USA

    Yong-Mei Cha MD

  2. Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA

    Win-Kuang Shen

Authors
  1. Yong-Mei Cha MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Win-Kuang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong-Mei Cha MD .

Editor information

Editors and Affiliations

  1. , Department of Internal Medicine, UMDNJ-RWJ Medical School, Robert Wood Johnson Pl. 1, New Brunswick, 08903-0019, New Jersey, USA

    Ihor Gussak

  2. , Gordon K. Moe Scholar, Masonic Medical Research Laboratory, Bleecker Street, Utica, 13501-1787, New York, USA

    Charles Antzelevitch

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Cha, YM., Shen, WK. (2013). Heart Failure and Sudden Death. In: Gussak, I., Antzelevitch, C. (eds) Electrical Diseases of the Heart. Springer, London. https://doi.org/10.1007/978-1-4471-4978-1_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4978-1_25

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4977-4

  • Online ISBN: 978-1-4471-4978-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation